Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia"

Next Previous
Trial Profile

Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia"

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary) ; Aripiprazole; Olanzapine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms Switch

Most Recent Events

  • 05 May 2023 Status changed from recruiting to completed.
  • 19 Jul 2022 Planned End Date changed from 30 Apr 2022 to 31 Dec 2022.
  • 19 Jul 2022 Planned primary completion date changed from 30 Apr 2022 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top